Response to

'Response to: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg

Eric F. Morand, Teodora Trasieva, Anna Berglind, Gabor Illei, Raj Tummala

Research output: Contribution to journalLetterOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Number of pages1
JournalAnnals of the Rheumatic Diseases
DOIs
Publication statusAccepted/In press - 2019

Keywords

  • disease activity
  • systemic lupus erythematosus
  • treatment

Cite this

@article{2b526c260d9d4b1ba3ef42af409a5464,
title = "Response to: 'Response to: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg",
keywords = "disease activity, systemic lupus erythematosus, treatment",
author = "Morand, {Eric F.} and Teodora Trasieva and Anna Berglind and Gabor Illei and Raj Tummala",
year = "2019",
doi = "10.1136/annrheumdis-2018-214487",
language = "English",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Response to

T2 - 'Response to: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg

AU - Morand, Eric F.

AU - Trasieva, Teodora

AU - Berglind, Anna

AU - Illei, Gabor

AU - Tummala, Raj

PY - 2019

Y1 - 2019

KW - disease activity

KW - systemic lupus erythematosus

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85055653268&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2018-214487

DO - 10.1136/annrheumdis-2018-214487

M3 - Letter

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -